Skip to contentP
Panacea Life Sciences Holdings, Inc.
P
PLSHPanacea Life Sciences Holdings, Inc. Q2 2020 · 10-Q
Revenue$6.16M$6.16M+10,143.0% vs Q2 2019 Net Income$655.22K$655.22KN/M vs Q2 2019 EPS Diluted$0.04$0.04N/M vs Q2 2019 Gross Profit$3,185,496N/M Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Panacea Life Sciences Holdings, Inc. · CIK 1552189 · Engraved from SEC EDGAR
Operating Cash Flowderived-$5,854,782N/M Free Cash Flowderived-$5,854,782N/M Margins · derivedGross margin51.7%+118.6 pt vs Q2 2019
Operating margin13.0%+3372.2 pt vs Q2 2019
Net margin10.6%+3378.3 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 19, 2020 · 50 d after period end